Brief: Salarius Pharmaceuticals Announces Interim Results From Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing Sarcoma And Fet-Rearranged Sarcomas

Decoy Therapeutics

01/12/2022 13:04

Dec 1 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * SALARIUS PHARMACEUTICALS ANNOUNCES INTERIM RESULTS FROM
PHASE
1/2 TRIAL OF SECLIDEMSTAT AS A TREATMENT FOR EWING SARCOMA AND
FET-REARRANGED SARCOMAS
    * SALARIUS PHARMACEUTICALS-60% CONFIRMED DISEASE CONTROL
RATE1 AND
7.4 MONTHS MEDIAN TIME TO TUMOR PROGRESSION FOR EWING SARCOMA
FIRST-RELAPSE PATIENTS
    * SALARIUS PHARMACEUTICALS-NO DISEASE PROGRESSION OBSERVED
IN
FIRST- OR SECOND-RELAPSE EWING SARCOMA PATIENTS WHO ACHIEVED
CONFIRMED DISEASE CONTROL

Source text for Eikon:  ID:nGNX7VL4vy 
Further company coverage:  SLRX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))